André Uchimura Bastos1, Gisele Oler1, Bruno Heidi Nakano Nozima1, Raquel Ajub Moysés1, Janete Maria Cerutti2. 1. Laboratório as Bases Genéticas dos Tumores da Tiroide Disciplina de Genética, Departamento de Morfologia e Genética, Universidade Federal de São Paulo (UNIFESP), Rua Pedro de Toledo, 669 - 11° andar, 04039-032 São Paulo, São Paulo, Brazil Disciplina de Cirurgia de Cabeça e Pescoço Departamento de Cirurgia, Universidade de São Paulo, São Paulo, São Paulo, Brazil. 2. Laboratório as Bases Genéticas dos Tumores da Tiroide Disciplina de Genética, Departamento de Morfologia e Genética, Universidade Federal de São Paulo (UNIFESP), Rua Pedro de Toledo, 669 - 11° andar, 04039-032 São Paulo, São Paulo, Brazil Disciplina de Cirurgia de Cabeça e Pescoço Departamento de Cirurgia, Universidade de São Paulo, São Paulo, São Paulo, Brazil j.cerutti@unifesp.br.
Abstract
BACKGROUND: Thyroid cancer incidence has dramatically increased worldwide over the last two decades. The rise is mostly due to an increased detection of small papillary thyroid carcinomas (PTCs) (≤20 mm), predominantly microPTC (≤10 mm). Although small tumors generally have an excellent outcome, a considerable percentage may have a more aggressive disease and worse prognosis. The clinical challenge is to preoperatively identify those tumors that are more likely to recur. AIM: To improve risk stratification and patient management, we sought to determine the prognostic value of BRAF V600E, NRAS or RET/PTC mutations in patients with PTC measuring <20 mm, mainly microPTC. METHODS: The prevalence of RET/PTC fusion genes was examined by quantitative RT-PCR. BRAF V600E and NRAS Q61 mutations were determined by PCR sequencing. To further elucidate why some small PTC are less responsive to radioactive iodine treatment therapy, we explored if these genetic alterations may modulate the expression of iodine metabolism genes (NIS, TPO, TG, TSHR and PDS) and correlated with clinico-pathological findings that are predictors of recurrence. RESULTS: This study shows that tumors measuring ≤20 mm exhibited higher prevalence of BRAF V600E mutation, which correlated with aggressive histopathological parameters, higher risk of recurrence, and lower expression of NIS and TPO. Although this correlation was not found when microPTC were evaluated, we show that tumors measuring 7-10 mm, which were positive for BRAF mutation, presented more aggressive features and lower expression of NIS and TPO. CONCLUSION: We believe that our findings will help to decide the realistic usefulness of BRAF V600E mutation as a preoperative marker of poor prognosis in small PTC, primarily in microPTC.
BACKGROUND: Thyroid cancer incidence has dramatically increased worldwide over the last two decades. The rise is mostly due to an increased detection of small papillary thyroid carcinomas (PTCs) (≤20 mm), predominantly microPTC (≤10 mm). Although small tumors generally have an excellent outcome, a considerable percentage may have a more aggressive disease and worse prognosis. The clinical challenge is to preoperatively identify those tumors that are more likely to recur. AIM: To improve risk stratification and patient management, we sought to determine the prognostic value of BRAFV600E, NRAS or RET/PTC mutations in patients with PTC measuring <20 mm, mainly microPTC. METHODS: The prevalence of RET/PTC fusion genes was examined by quantitative RT-PCR. BRAFV600E and NRAS Q61 mutations were determined by PCR sequencing. To further elucidate why some small PTC are less responsive to radioactive iodine treatment therapy, we explored if these genetic alterations may modulate the expression of iodine metabolism genes (NIS, TPO, TG, TSHR and PDS) and correlated with clinico-pathological findings that are predictors of recurrence. RESULTS: This study shows that tumors measuring ≤20 mm exhibited higher prevalence of BRAFV600E mutation, which correlated with aggressive histopathological parameters, higher risk of recurrence, and lower expression of NIS and TPO. Although this correlation was not found when microPTC were evaluated, we show that tumors measuring 7-10 mm, which were positive for BRAF mutation, presented more aggressive features and lower expression of NIS and TPO. CONCLUSION: We believe that our findings will help to decide the realistic usefulness of BRAFV600E mutation as a preoperative marker of poor prognosis in small PTC, primarily in microPTC.
Authors: F Cecoli; E M Ceresola; V Altrinetti; M Cabria; M Cappagli; A Montepagani; C M Cuttica; U Filippi; D Saverino; M Raffa; M Caputo; F Minuto; M Giusti; M Bagnasco Journal: Eur Thyroid J Date: 2016-06-02
Authors: Maria José Carregosa Pinheiro Dos Santos; André Uchimura Bastos; Vitor Rodrigues da Costa; Rosana Delcelo; Susan Chow Lindsey; Gabriel Avelar Colozza-Gama; Hongzhuang Peng; Frank J Rauscher; Gisele Oler; Janete Maria Cerutti Journal: Endocr Pathol Date: 2018-09 Impact factor: 3.943
Authors: Claudio R Cernea; Leandro Luongo Matos; Cecília Eugênio; Giovanna Mattos Ferreira; Yasmin Sa Cerqueira; Ana Kober N Leite; Felipe A B Vanderlei; Dorival de Carlucci; Renato N Gotoda; Flávio C Hojaij; Vergilius J F Araújo-Filho Journal: Curr Oncol Rep Date: 2022-01-21 Impact factor: 5.075